2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
88
Lymphoma, Follicular
50
Lymphoma, Non-Hodgkin
36
Lymphoma, Large B-Cell, Diffuse
29
Lymphoma
29
Lymphoma, Mantle-Cell
26
Lymphoma, B-Cell, Marginal Zone
22
Lymphoma, B-Cell
18
Recurrence
13
Neoplasms
11
Leukemia
7
Leukemia, B-Cell
5
Burkitt Lymphoma
5
Leukemia, Hairy Cell
4
Waldenstrom Macroglobulinemia
3
Neoplasm, Residual
3
Melanoma
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bronchiolitis Obliterans Syndrome
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Tumor Lysis Syndrome
1
Solid Cancers
1
Interventions
pembrolizumab
156
Gemcitabine
140
Capecitabine
123
Paclitaxel
120
Fluorouracil
117
Oxaliplatin
110
Bevacizumab
106
Nivolumab
99
Leucovorin
97
Docetaxel
97
Cisplatin
89
Radiosurgery
88
Irinotecan
87
Carboplatin
85
Cetuximab
72
Cyclophosphamide
71
Magnetic Resonance Spectroscopy
68
Specimen Handling
60
Radiotherapy
60
Trastuzumab
59
Biopsy
59
Ipilimumab
53
Drug Therapy
51
Everolimus
48
Pemetrexed
46
Albumin-Bound Paclitaxel
45
130-nm albumin-bound paclitaxel
44
Doxorubicin
42
Fulvestrant
40
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
obinutuzumab
×
Clear all
NCT04880863
2025-03-03
NT-NAP-102-1
NeoTX Therapeutics Ltd.
Phase 2
Completed
38 enrolled
13 charts